Drug Profile

GTX 011 - GAT Therapeutics

Alternative Names: GTX-011 - GAT Therapeutics; GTX-11

Latest Information Update: 31 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GAT Therapeutics
Class Antifibrotics; Hepatoprotectants; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Idiopathic pulmonary fibrosis
Preclinical Hepatic fibrosis; Non-alcoholic steatohepatitis; Systemic scleroderma
Research Myelofibrosis

Most Recent Events

31 Dec 2024 Phase-I clinical trials in Idiopathic pulmonary fibrosis(unspecified route) before December 2024 (GAT Therapeutics pipeline, December 2024)
31 Dec 2024 Preclinical trials in Systemic scleroderma in Spain (unspecified route) before December 2024 (GAT Therapeutics pipeline, December 2024)
07 Sep 2024 Pharmacodynamics data from a preclinical trial in Idiopathic pulmonary fibrosis presented at the 34^th Annual Congress of the European Respiratory Society (ESR-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com